CA-HEPTAGON
Heptagon (www.hptg.com ), an industry leader in 3D imaging, sensing and illumination solutions for the Internet of Things (IoT) and Smart Devices, today announced it has shipped over 2 billion units to customers. The company, which is headquartered in Singapore, recently opened a new factory with expanded capacity to ship 1 billion units per year. Heptagon serves some of the largest makers of mobile and IoT products in the world. Its success is attributed to relentless dedication to innovation, consistently delivering top-quality, high-performance products to market quickly, and leading edge wafer level manufacturing capabilities that meet the needs of the fast-paced and rapidly-evolving IoT and smart device industries.
"We are delighted to announce this latest milestone in our rapid growth and see this as ongoing acceptance by the market of our innovative, world-class products," says Christian Tang-Jespersen, CEO and President of Heptagon. "We look forward to continuing our strong growth and reaching our next billion units shipped milestone.”
"We are well positioned to pursue new market opportunities with the expansion of our fab in Woodlands, Singapore and the opening of our new factory in Ang Mo Kio, Singapore," says S.C. Leong, Heptagon’s Chief Operating Officer. “We remain committed to uncompromising quality and our proven ability to move quickly from white board to shipping 100s of millions of units."
In addition to opening the new factory in Singapore, Heptagon has expanded its sales, marketing and engineering presence in Silicon Valley as a result of strong customer interest in the company’s product and miniaturization, integration, optical and electrical design expertise. Heptagon’s newly created Silicon Valley Labs and Executive Briefing Center showcase the latest interface and sensing technologies while providing convenient access for the innovators and decision makers in Silicon Valley.
With in-depth and unique knowledge and expertise in all major 3D imaging and sensing technologies including stereo vision, structured light and Time-of-Flight (ToF), Heptagon is ready to address a fast-growing market segment of 3D. The company’s products continue to push the boundaries of what is possible in 3D today. As a pioneer of ToF imaging, it recently introduced the industry’s first multipoint 3D ranging sensor for mobile application. Further, its proprietary technologies like adaptive stereo enables indoor and outdoor imaging in a single solution and create a unique platform for 3D capturing where the adaptive illumination technology powers interference free multi-user applications as needed in collaborative augmented reality, automotive cockpits and digital signage.
The need to integrate heterogeneous technologies in miniaturized packages is rapidly becoming the enabler of next generation products in mobile, wearables and IoT. Over 20 years of innovation in technology, manufacturing and operations, as well as a rigorous supply chain management form the foundation for Heptagon’s differentiation and uniquely positions the company to innovate and rapidly bring world-class products to market.
About Heptagon
Heptagon (www.hptg.com ) provides complete 3D/imaging, illumination and optical sensing solutions for smart devices and the internet of things. With over 2 billion units shipped and 20 years of industry firsts in miniaturizing and integrating complex hardware and software systems, Heptagon has industry leading technology and services to enhance our customer’s competitiveness. Backed by world-class investors, Heptagon is a global company with research and development, sales and customer services teams located in Singapore, Zurich Switzerland, in Silicon Valley USA, and Shenzhen China.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160221005200/en/
Contact:
Heptagon
Scott Filler +1 408-329-8920
pr@hptg.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom